Providers

Underdosing, poor spleen response, and transfusion dependence drive inferior survival outcomes in intermediate-1 myelofibrosis.

Mepolizumab showed significant real-world improvements in asthma outcomes, reducing exacerbations and corticosteroid use in severe eosinophilic asthma.

By 2040, advanced metabolic dysfunction–associated steatohepatitis (MASH) is projected to rise by at least 20% in the 9 countries assessed.

Among survey respondents, approximately 80% reported experiencing stigma, including feelings of embarrassment, negative judgment, or being treated differently, because of their condition.

Among patients with hematologic malignancies who were diagnosed with COVID-19, about one-quarter experienced critical illness, and most of those patients died.

As the prevalence of both chronic kidney disease (CKD) and heart failure (HF) increases, therapies targeting shared pathways are one of the most promising strategies to alter the trajectory of these diseases.

The drug lowered inflammation, oxidative stress, and endothelial injury markers in women with INOCA and coronary microvascular dysfunction.

This article presents a case study of how stakeholders in one state came together to integrate practice and research that is a step beyond a learning health care system.

Patients’ misperceptions of statins and physicians’ limited knowledge of a hypercholesterolemia safety-net program warrant additional interventions to reduce barriers and improve care.

Despite overall growth in the radiology workforce, the proportion of pediatric radiologists specifically decreased from 2016 to 2023.

This article reviews the safety, efficacy, and regulatory concerns related to compounded semaglutide, with a focus on how health care providers can offer guidance and education to patients.

Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).

The treatment also showed signs of metabolic gains, with more benefit seen with the 50-mg dose than the 28-mg.

The findings add confidence to the role of ritlecitinib as a treatment option for severe alopecia areata while pointing the way toward more personalized approaches.

Despite reduced immune responses, immunization lowers infection rates and remains central to supportive care in patients with multiple myeloma.

A new joint guideline from the American Heart Association and the American College of Cardiology emphasizes early treatment, close perinatal blood pressure monitoring, and incorporating the PREVENT risk calculator to personalize care.

Psoriasis received the second-most funding of any pediatric dermatology condition, even though it ranked fifth in terms of disease burden.

Patients with small cell lung cancer (SCLC) experienced better responses to immune checkpoint inhibitors if they had higher levels of NOTCH1 expression in a recent study.

The findings may inform future studies on the therapeutic strategy for patients with small cell lung cancer (SCLC).

While observational studies have previously pointed to an association, being able to identify causation has been difficult due to overlapping risk factors and confounding variables.

A primary care–based collaborative care model significantly cut opioid use, though mental health outcomes remained unchanged.

Givinostat shows promise in delaying Duchenne muscular dystrophy (DMD) progression, enhancing mobility, and maintaining safety in long-term treatment.

Patients with severe sickle cell disease experienced significant quality of life improvements after receiving exagamglogene autotemcel gene therapy.

Families reported quality of life improvements when they used peanut oral immunotherapy instead of simply avoiding peanuts.

A new patient-centered methadone restart protocol enhances opioid use disorder treatment, improving safety and retention while personalizing care.

Targeted “Food is Medicine” interventions can help individuals with diet-sensitive chronic conditions improve their health, but nationally representative survey and qualitative interviews showed low awareness despite high interest among respondents.

Lebrikizumab shows sustained efficacy and safety in managing moderate to severe atopic dermatitis over 3 years, reducing the need for rescue therapies.

By week 16, researchers found 87.8% of patients achieved a satisfactory humoral response.

Metabolic syndrome severity is a meaningful marker of chronic kidney disease risk even when patients do not have other major risk factors.

Despite the findings, existing data around cardiovascular risk in chronic lymphocytic leukemia (CLL) are limited, and more comprehensive information is needed to draw strong conclusions.